Physician profile
Mary Dickerson
NPI 1972543445
$17,682.87
in general payments reported to CMS, 2019-2025
36 companies · $2,967 in 2025
The $2,967 reported for 2025 was more than what 96% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,542 · 2020: $1,102 · 2021: $1,969 · 2022: $2,675 · 2023: $3,739 · 2024: $3,690 · 2025: $2,967.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,706 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $417 · Education: $263 · Grant: $10.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,705.51 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $416.67 |
| Education | $262.87 |
| Grant | $10.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,557.61 | 2019-2025 | Skyrizi, Rinvoq, Humira |
| Pfizer INC. | $1,330.18 | 2019-2025 | |
| Galderma Laboratories, L.P. | $1,155.00 | 2019-2025 | Nemluvio, Aklief |
| Genzyme Corporation | $1,152.38 | 2019-2025 | |
| Ucb, INC. | $1,035.17 | 2019-2025 | Bimzelx, Cimzia |
| Janssen Biotech, INC. | $938.90 | 2019-2025 | Tremfya, Stelara, Simponi |
| Lilly USA, LLC | $794.19 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Merz North America, INC. | $774.20 | 2022-2025 | Xeomin |
| Novartis Pharmaceuticals Corporation | $734.26 | 2020-2025 | |
| Regeneron Healthcare Solutions, INC. | $717.33 | 2021-2025 | Dupixent, Libtayo |
| Incyte Corporation | $695.92 | 2021-2025 | Opzelura |
| Amgen INC. | $691.27 | 2019-2025 | Otezla, Otezla |
| Leo Pharma INC. | $579.71 | 2019-2025 | Adbry, Anzupgo |
| E.R. Squibb & Sons, L.L.C. | $461.11 | 2022-2025 | Sotyktu |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $450.40 | 2019-2024 | Siliq, Targretin, Jublia |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $386.36 | 2023-2025 | Zoryve |
| Sun Pharmaceutical Industries INC. | $384.20 | 2019-2025 | Ilumya |
| Allergan, INC. | $286.50 | 2019-2022 | |
| Mayne Pharma Commercial LLC | $217.38 | 2019-2024 | |
| Epi Health, LLC | $207.38 | 2019-2022 | |
| Genentech USA, INC. | $172.54 | 2019-2023 | Erivedge |
| Boehringer Ingelheim Pharmaceuticals, INC. | $131.38 | 2022-2025 | Spevigo, Cyltezo |
| Celgene Corporation | $123.29 | 2019 | |
| Almirall LLC | $121.06 | 2019-2025 | Klisyri |
| Dermira, INC. | $77.32 | 2019-2020 | |
| Biofrontera INC. | $76.23 | 2019-2022 | |
| Revance Therapeutics, INC. | $75.77 | 2024 | Daxxify |
| Dermavant Sciences, INC. | $71.95 | 2022-2023 | Vtama |
| Botanix Sb INC | $61.24 | 2025 | Sofdra |
| Journey Medical Corporation | $55.31 | 2022-2025 | |
| Helsinn Therapeutics (U.S.), INC. | $48.20 | 2019-2023 | Valchlor |
| Aclaris Therapeutics, INC. | $36.30 | 2019 | |
| Acacia Pharma INC | $22.86 | 2022 | |
| Conmed Corporation | $22.84 | 2025 | Visiclear |
| Verrica Pharmaceuticals INC. | $22.14 | 2023 | Ycanth |
| Strata Skin Sciences, INC. | $14.99 | 2024 | Xtrac |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Dickerson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.